Designing synthetic vaccines for HIV

Expert Review of Vaccines

Volumn 14, Issue 6, 2015, Pages 815-831

  Fernández Tejada, Alberto ^a   Haynes, Barton F ^b,c   Danishefsky, Samuel J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AIDS; broadly neutralizing antibody; carbohydrates; glycopeptides; glycosylation; gp120; HIV vaccine design; synthetic antigen

Indexed keywords

CARBOHYDRATE ANTIGEN; EPITOPE; GLYCAN; GLYCOPEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; OLIGOSACCHARIDE; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGENICITY; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN GLYCOSYLATION; REVIEW; BLOOD; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; VACCINES, SYNTHETIC;

EID: 84929306309     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1027690     Document Type: Review

References (81)

1. Gallo C, Montagnier L. The discovery of HIV as the cause of AIDS. N Eng J Med 2003;349:2283-5.
2. UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS. Available from: www.unaids.org/en/media/unaids/ contentassets/documents/epidemiology/ 2013/gr2013/ UNAIDS-Global-Report-2013-en.pdf
3. McMichael AJ, Koff WC. Vaccines that stimulate T cell immunity to HIV-1: the next step. Nature Immunol 2014;15:319-22.
4. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med 2012;63: 95-111.
5. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-6.
6. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6: 207-10.
7. Cohen J. Clinical research. A setback and an advance on the AIDS vaccine front. Science 2003;300:28-9.
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20.
9. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines 2010;9:997-1005.
10. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275-86.
11. Karpenko LI, Bazhan SI, Antonets DV, Belyakov IM. Novel approaches in polyepitope T-cell vaccine development against HIV-1. Expert Rev Vaccines 2014;13:155-73.
12. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 2010;464: 224-31.
13. Haynes BF, Verkoczy L. Host controls of HIV neutralizing antibodies. Science 2014;344:588-9.
14. Verkoczy L, Chen Y, Zhang J, et al. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region- associated autoreactivity limits T-dependent responses. J Immunol 2013;191:2538-50.
15. Montefiori DC, Mascola JR. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr Opin HIV AIDS 2009;4:347-51.
16. Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/ rAd5 HIV-1 preventive vaccine. N Engl J Med 2013;369:2083-92.
17. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010;33:542-54.
18. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding natures pathways. Immunol Rev 2013;254:225-44.
19. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012;337:183-6.
20. Huang J, Kang BH, Pancera M, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014;515: 138-42.
21. Falkowska E, Le KM, Ramos A, et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014;40:657-68.
22. Scharf L, Scheid JF, Lee JH, et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Reports 2014;7:785-95.
23. Blattner C, Lee JH, Sliepen K, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 2014;40:669-80.
24. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998;280:1884-8.
25. Johnson WE, Desrosiers RC. Viral persistence: HIVs strategies of immune system evasion. Annu Rev Med 2002;53: 499-518.
26. Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013;496:469-76.
27. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003;422:307-12.
28. Kong L, Lee JH, Doores KJ, et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 2013;20:796-803.
29. Sok D, Doores KJ, Briney B, et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med 2014;6:236ra63.
30. Garces F, Sok D, Kong L, et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 2014;159: 69-79.
31. Doores KJ, Bonomelli C, Harvey DJ, et al. Envelope glycans of immunodeficiency virions are entirely oligomannose antigens. Proc Natl Acad Sci USA 2010;107:13800-5.
32. Zhu X, Borchers C, Bienstock RJ, Tomer KB. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 2000;39:11194-204.
33. Go EP, Hewawasam G, Liao HX, et al. Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 2011;85:8270-84.
34. Go EP, Liao HX, Alam SM, et al. Characterization of host-cell line specific glycosylation profiles of early transmitted/ founder HIV-1 gp120 envelope proteins. J Proteome Res 2013;12:1223-34.
35. Bonomelli C, Doores KJ, Dunlop DC, et al. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 2011;6:e23521.
36. Trkola A, Purtschner M, Muster T, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996;70:1100-8.
37. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009;5:e1000433.
38. Sanders RW, Venturi M, Schiffner L, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002;76:7293-305.
39. Scanlan CN, Pantophlet R, Wormald MR, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of a1!2 mannose residues on the outer face of gp120. J Virol 2002;76:7306-21.
40. Calarese DA, Scanlan CN, Zwick MB, et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003;300: 2065-71.
41. Wang LX, Ni J, Singh S, Li H. Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design. Chem Biol 2004;11: 127-34.
42. Lee HK, Scanlan CN, Huang CY, et al. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody. Angew Chem Int Ed 2004;43:1000-3.
43. Adams EW, Ratner DM, Bokesch HR, et al. Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycan-dependent gp120/protein interactions. Chem Biol 2004;11:875-81.
44. Calarese DA, Lee HK, Huang CY, et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci USA 2005;102:13372-7.
45. Mandal M, Dudkin VY, Geng X, Danishefsky SJ. In pursuit of carbohydrate-based HIV vaccines, part 1: the total synthesis of hybrid-type gp120 fragments. Angew Chem Int Ed 2004;43:2557-61.
46. Geng X, Dudkin VY, Mandal M, Danishefsky SJ. In pursuit of carbohydrate-based HIV vaccines, part 2: the total synthesis of high-mannose-type gp120 fragments - evaluation of strategies directed to maximal convergence. Angew Chem Int Ed 2004;43:2562-5.
47. Likhosherstov LM, Novikova OS, Derevitskaja VA, Kochetkov NK. A new simple synthesis of amino sugar b-D-glycosylamines. Carbohydr Res 1986;146:C1-6.
48. Cohen-Anisfeld ST, Lansbury PT Jr. A practical, convergent method for glycopeptide synthesis. J Am Chem Soc 1993;115:10531-7.
49. Dudkin V, Orlova M, Geng X, et al. Toward fully synthetic carbohydrate-based HIV antigen design: on the critical role of bivalency. J Am Chem Soc 2004;126: 9560-2.
50. Krauss IJ, Joyce JG, Finnefrock AC, et al. Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody. J Am Chem Soc 2007;129:11042-4.
51. Joyce JG, Krauss IJ, Song HC, et al. An oligosaccharide-based HIV-1.
52. Li H, Wang LX. Design and synthesis of a template-assembled oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12. Org Biomol Chem 2004;2:483-8.
53. Ni J, Song H, Wang Y, et al. Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates. Bioconjug Chem 2006;17:493-500.
54. Wang J, Li H, Zou G, Wang LX. Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study. Org Biomol Chem 2007;5:1529-40.
55. Wang SK, Liang PH, Astronomo RD, et al. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci USA 2008;105:3690-5.
56. Astronomo RD, Lee HK, Scanlan CN, et al. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J Virol 2008;82:6359-68.
57. Astronomo RD, Kaltgrad E, Udit AK, et al. Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol 2010;17: 357-70.
58. Agrawal-Gamse C, Luallen RJ, Liu B, et al. Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans. J Virol 2011;85:470-80.
59. Doores KJ, Fulton Z, Hong V, et al. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc Natl Acad Sci USA 2010;107:17107-12.
60. Walker LM, Phogat SK, Chan-Hui P-Y, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:285-9.
61. Doores KJ, Burton DR. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 2010;84:10510-21.
62. Bonsignori M, Hwang K-K, Chen X, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011;85: 9998-10009.
63. McLellan JS, Pancera M, Carrico C, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011;480:336-43.
64. Aussedat B, Vohra Y, Park PK, et al. Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. J Am Chem Soc 2013;135:13113-20.
65. Wang P, Aussedat B, Vohra Y, Danishefsky SJ. An advance in the chemical synthesis of homogeneous N-linked glycopolypeptides by convergent aspartylation. Angew Chem Int Ed 2012;51: 11571-5.
66. Alam SM, Dennison SM, Aussedat B, et al. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc Natl Acad Sci USA 2013;110:18214-19.
67. Liao HX, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013;38:176-86.
68. Wan Q, Danishefsky SJ. Free-radical-based, specific desulfurization of cysteine: a powerful advance in the synthesis of polypeptides and glycopolypeptides. Angew Chem Int Ed 2007;46:9248-52.
69. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30:423-33.
70. Adam SM, Liao HX, Tomaras GD, et al. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 2013;87:1554-68.
71. Julien JP, Lee JH, Cupo A, et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA 2013;110:4351-6.
72. de Souza MS, Ratto-Kim S, Chuenarom W, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012;188:5166-76.
73. Amin MN, McLellan JS, Huang W, et al. Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. Nat Chem Biol 2013;9:521-6.
74. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 2013;20:804-13.
75. Shivatare SS, Chang SH, Tsai TI, et al. Efficient convergent synthesis of bi-, tri-, and tetra-antennary complex type N-glycans and their HIV-1 antigenicity. J Am Chem Soc 2013;135:15382-91.
76. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011;477:466-70.
77. Pejchal R, Doores KJ, Walker LM, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011;334:1097-103.
78. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004;4:199-210.
79. Li H, Li B, Song H, et al. Chemoenzymatic synthesis of HIV-1 V3 glycopeptides carrying two N-glycans and effects of glycosylation on the peptide domain. J Org Chem 2005;70:9990-6.
80. Orwenyo J, Amin MN, Lomino JV, Wang LX. Synthesis of homogeneous HIV-1 V3 glycopeptides for characterizing the glycan specificity of glycan-dependent HIV-neutralizing antibodies. CARB-64. Abstracts of Papers 247th National Meeting of the American Chemical Society, March 16-20, 2014, Dallas, TX
81. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30:423-33.